增强的线粒体Mrs2-Mg2+信号驱动了肺动脉高血压大鼠中的线粒体功能障碍
Ruo-Nan Chen1, Xue-Qin Weng1, Yan Yan2
1Key Laboratory of Fujian Province Universities on Ion Channel and Signal Transduction in Cardiovascular Diseases, Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China (R.-N.C., X.-Q.W., Q.-Y.C., L.L., X.-L.Z., L.-X.G., M.-J.L., D.-C.L.).
Hypertension (Dallas, Tex. : 1979)
|March 16, 2026
概括
由Mrs2驱动的线粒体过载会破坏细胞平衡,并促进肺动脉高血压 (PAH). 针对Mrs2为PAH提供了一个潜在的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 线粒体生理学线粒体生理学
- 细胞的新陈代谢
背景情况:
- 肺动脉高血压 (PAH) 的特点是离子失衡和血管重塑.
- 细胞质 ([Mg2+]i) 枯竭是PAH的已知特征,但线粒体 (mMg2+) 的作用尚不清楚.
- 线粒体RNA拼接2 (Mrs2) 是mMg2+流入的主要载体,并被假设参与PAH病变发生.
研究的目的:
- 研究Mrs2在线粒体平衡中的作用及其对PAH的贡献.
- 阐明通过Mrs2介导的mMg2+失调影响PAH细胞代谢和血管重塑的机制.
- 评估针对PAH中Mrs2的治疗潜力.
主要方法:
- 机理学研究使用来自单克罗他林诱导的PAH大鼠的原发性肺动脉光滑肌细胞.
- 在Su5416/低氧模型中对代谢和线粒体变化的验证.
- 在体内评估腺相关病毒介导的Mrs2敲击在单类PAH大鼠.
主要成果:
- 在PAH细胞中,Mrs2上调和Slc41a3下调导致mMg2+过载和[Mg2+]i耗尽.
- 过多的mMg2+通过酸盐脱酶酸化和HIF-1α激活促进了糖解.
- 在mMg2+,乳酸和细胞质 ([Ca2+]i) 之间的反循环过载加剧了线粒体功能障碍,促进了细胞过度增殖和血管重塑.
- Mrs2 knockdown可以逆转这些有害影响,恢复线粒体功能,改善PAH大鼠的血液动力学.
结论:
- 异常的Mrs2介导的mMg2+信号破坏了离子和代谢的平衡,导致线粒体功能障碍和PAH.
- 针对以Mrs2为中心的轴,为中断PAH进展提供了一个潜在的治疗策略.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
6.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.1K
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
Electron Transport Chain: Complex I and II
19.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.4K
Pulmonary Hypertension: Classification and Pathogenesis
783
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
783
MAPK Signaling Cascades
9.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
620
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
620


